$4.20
0.020.48%
Last update: Nov 10, 8:12 AM
Opus Genetics Inc (IRD) Stock Price, Quote, News & History
IRDNASDAQ
Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
You can purchase shares of Opus Genetics (NASDAQ:IRD) through any online brokerage.
Other companies in Opus Genetics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Opus Genetics has a consensus price target of $11.94.
The stock price for Opus Genetics (NASDAQ: IRD) is $4.2 last updated November 10, 2026 at 8:12 AM EST.
There are no upcoming dividends for Opus Genetics.
Opus Genetics does not have any upcoming earnings scheduled.
There is no upcoming split for Opus Genetics.
Opus Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline...
